Quoin Pharmaceuticals Completes Merger and Will Commence Trading on Nasdaq Capital Market under Ticker Symbol “QNRX”
28 oct. 2021 18h25 HE
|
Quoin Pharmaceuticals, Ltd.
Ashburn, VA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals, Ltd., (NASDAQ: QNRX) (the “Company”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced...
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals
15 oct. 2021 16h01 HE
|
Cellect Biotechnology Ltd.
Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and distribution date for the contingent value rights (the...
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals
27 sept. 2021 09h10 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with...
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.
02 sept. 2021 16h20 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: “APOP”), announced the first ApoGraftTM transplantation in a Leukemia...
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results
24 août 2021 16h16 HE
|
Cellect Biotechnology Ltd.
Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a...
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals
13 août 2021 16h20 HE
|
Cellect Biotechnology Ltd.
Special General Meeting of Shareholders Scheduled for September 19, 2021 Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative...
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals
16 juin 2021 18h58 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced...
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial
19 avr. 2021 08h00 HE
|
Cellect Biotechnology Ltd.
Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today...
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
29 mars 2021 09h29 HE
|
Cellect Biotechnology Ltd.
TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today...
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
24 mars 2021 17h26 HE
|
Cellect Biotechnology Ltd.
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined...